– Meeting adjourned to October 10, 2022 at 11 a.m. PST
– GTB encourages all stockholders of document on August 8, 2022 who’ve not but voted
– to take action by 11:59 p.m. PST Time on October 9, 2022
BRISBANE, CALIFORNIA, Oct. 04, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a scientific stage immuno-oncology firm centered on growing revolutionary therapeutics primarily based on the Company’s proprietary pure killer (NK) cell engager, TriKE® platform, as we speak introduced that its 2022 Special Shareholders Meeting has been adjourned to October 10, 2022 at 11 a.m. PST because of lack of quorum for its beforehand scheduled assembly. The adjournment supplies the Company with extra time to solicit the mandatory proxies from its shareholders to attain a quorum on the Special Shareholders Meeting.
The proposal for the Special Shareholders Meeting stays the ratification by shareholders of the inclusion of discretionary votes by brokers and different nominees holding shares for useful homeowners within the approval of the proposal submitted on the Company’s 2022 Annual Meeting to scale back the Company’s licensed shares of widespread inventory from 750 million to 250 million.
The transaction of business on the Special Shareholders Meeting requires a quorum of greater than one-half of the excellent shares of the Company entitled to vote, represented in individual or by proxy. The document date for the adjourned Special Shareholders Meeting stays the shut of business on August 8, 2022. Shareholders who’ve already voted don’t have to recast their votes except they want to change their votes. Proxies beforehand submitted can be voted on the reconvened assembly except correctly revoked. Shareholders who haven’t already voted or want to change their vote are inspired to take action promptly utilizing the directions offered of their voting instruction type or proxy card.
The Company urges all shareholders to vote their shares instantly to make sure their votes rely in time for the Special Shareholders Meeting on October 10, 2022. If you might have any questions or require any help in voting your shares, please contact GT Biopharma.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a scientific stage biopharmaceutical firm centered on the event and commercialization of immuno-oncology therapeutic merchandise primarily based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and improve the most cancers killing talents of a affected person’s immune system’s pure killer cells. GT Biopharma has an unique worldwide license settlement with the University of Minnesota to additional develop and commercialize therapies utilizing TriKE® expertise. For extra info, please go to gtbiopharma.com.
Forward-Looking Statements
Certain statements on this press launch might represent “forward-looking statements” relating to future occasions and our future outcomes. All statements apart from statements of historic details are statements that may very well be deemed to be forward-looking statements. These statements are primarily based on present expectations, estimates, forecasts, and projections concerning the markets by which we function and the beliefs and assumptions of our administration. Words reminiscent of “expects,” “anticipates,” “targets,” “goals,” “projects”, “intends,” “plans,” “believes,” “seeks,” “estimates,” “endeavors,” “strives,” “may,” or variations of such phrases, and related expressions are meant to determine such forward-looking statements. Readers are cautioned that these forward-looking statements are topic to a quantity of dangers, uncertainties and assumptions which are troublesome to foretell, estimate or confirm. Therefore, precise outcomes might differ materially and adversely from these expressed in any forward-looking statements. Such dangers and uncertainties embrace these elements described in our most up-to-date annual report on Form 10-Okay, as such could also be amended or supplemented by subsequent quarterly studies on Form 10-Q, or different studies filed with the Securities and Exchange Commission. Readers are cautioned to not place undue reliance on these forward-looking statements. The forward-looking statements are made solely as of the date hereof, and we undertake no obligation to publicly launch the outcome of any revisions to those forward-looking statements. For extra info, please confer with our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contacts:
LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
212-915-2577
